Last updated on February 2020

A Dose Escalation Study Of PF 06939999 In Participants With Advanced Or Metastatic Solid Tumors

Brief description of study

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

Clinical Study Identifier: NCT03854227

Find a site near you

Start Over

Inova Schar Cancer Institute

Annandale, VA United States
  Connect »

Inova Schar Cancer Institute

Fairfax, VA United States
  Connect »